In its May-ended quarter, the drugstore chain recorded net income of 91 cents a share, 3 cents short of what analysts surveyed by Thomson Reuters expected. Revenue of $19.4 billion missed expectations of $19.48 billion.
Before market open, shares are down 1% to $73.
Separately, TheStreet Ratings team rates WALGREEN CO as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate WALGREEN CO (WAG) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow."
- You can view the full analysis from the report here: WAG Ratings Report